ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Zomedica Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Zomedica Corp. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Devices | $26.65M | $26.08M | $26.20M | $25.93M | $25.75M | $25.28M | $24.85M | $24.70M | $24.19M | $24.25M | $23.81M | $22.84M | 72.3% | +3.5% |
| Development Services | $6.42M | – | $3.03M | – | – | – | – | – | – | – | – | – | 17.4% | – |
| Diagnostics | $3.81M | $3.21M | $2.80M | $2.87M | $2.61M | $2.25M | $2.43M | $2.03M | $1.89M | $1.72M | $1.38M | $1.16M | 10.3% | +46.1% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $23.01M | $21.65M | $20.68M | $19.75M | $19.08M | $18.15M | $17.66M | $17.13M | $16.90M | $16.57M | $16.31M | $15.47M | 62.4% | +20.6% |
| Capital | $9.46M | $9.27M | $9.25M | $9.10M | $9.15M | $9.22M | $9.49M | $9.46M | $9.07M | $9.30M | $8.79M | $8.45M | 25.6% | +3.4% |
| Engineering | $4.20M | – | $1.98M | – | – | – | – | – | – | – | – | – | 11.4% | – |
| Other | $213.00K | $187.00K | $123.00K | $118.00K | $129.00K | $150.00K | $131.00K | $135.00K | $103.00K | $92.00K | $85.00K | $85.00K | 0.6% | +65.1% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $31.09M | $28.79M | $26.46M | $24.02M | $23.11M | $22.45M | $22.56M | – | – | – | – | – | 84.3% | +34.5% |
| Foreign countries | $5.78M | $5.54M | $5.57M | $5.44M | $5.25M | $5.08M | $4.73M | – | – | – | – | – | 15.7% | +10.2% |
From the segment and revenue-disaggregation notes of Zomedica's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.